Alzinova publishes the Annual Report for 2021
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, today announces that the Company’s 2021 Annual Report has been published.“2021 was a successful year for Alzinova when we started the first clinical study with the therapeutic vaccine, ALZ-101, in Alzheimer’s patients and we established new collaborations with leading groups in the fight against Alzheimer’s,” says Kristina Torfgård, CEO of Alzinova. The Annual Report, which is attached in the press release, can also be downloaded from the company’s Swedish website, www.